Prime Medicine, Inc. cotiza a 3.34 USD y tiene una capitalización bursátil de $606M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson …
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.24 | $-0.28 | $-0.24 |
| Estimado | $-0.23 | $-0.26 | $-0.25 | $-0.26 |
| Sorpresa | — | +7.7% | -12.0% | +7.7% |
| Métrica | PRME | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -4498.1% | -38.6% | -4459.4% |
| Net Margin | -4342.4% | -33.6% | -4308.9% |
| FCF Margin | -3607.4% | -13.9% | -3593.5% |
| ROE | -166.4% | -40.4% | -126.0% |
| ROA | -58.7% | -32.0% | -26.7% |
| Current Ratio | 4.84 | 2.84 | +2.00 |
| Debt / Equity | — | 0.28 | — |